MET and cancer: Previous studies have associated the overexpression of MET with cancer progression and prognosis including oral cancer 15, 17, 19, and the MET polymorphisms were suggested to be associated with cancer development and prognosis in various cancers such as small cell lung cancer 20, gastric cancer 21, 22, hepatocellular carcinoma (HCC) 23, and papillary thyroid carcinoma 23.